Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 4/20 | 0.46 |
| ▸ | TK1 | P04183 | 7/20 | 0.46 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | TK2 | O00142 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12848323 | 1.00 | TOP2A (0.46) | TOP2ATK1DHFRTK2 | |
| SCHEMBL1417955 | 1.00 | TOP2A (0.46) | TOP2ATK1DHFRTK2 | |
| SCHEMBL25400484 | 0.82 | DUT (0.45) | TOP2A | |
| SCHEMBL26280079 | 0.82 | DUT (0.45) | TOP2A | |
| SCHEMBL1418156 | 0.79 | TK1 (0.50) | TK1DHFRTK2 | |
| SCHEMBL6830807 | 0.76 | TOP2A (0.49) | TOP2ATK1DHFRTK2 | |
| SCHEMBL6830804 | 0.76 | TOP2A (0.49) | TOP2ATK1DHFRTK2 | |
| SCHEMBL23270835 | 0.76 | TOP2A (0.51) | TOP2ATK1DHFR | |
| SCHEMBL12942602 | 0.76 | TOP2A (0.51) | TOP2ATK1DHFR | |
| SCHEMBL24059076 | 0.76 | TOP2A (0.51) | TOP2ATK1DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2298783-B1 | Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections | UNIV YALE (US) | 2017-12-06 | — | — | EP | disclosed |
| US-9126971-B2 | Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections | YALE UNIVERSITY (US) | 2015-09-08 | — | — | US | disclosed |
| US-20120252751-A1 | ANTI-VIRAL NUCLEOSIDE ANALOGS AND METHODS FOR TREATING VIRAL INFECTIONS, ESPECIALLY HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-04 | — | — | US | disclosed |
| US-8193165-B2 | Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections | YALE UNIVERSITY (US) | 2012-06-05 | — | — | US | disclosed |
| EP-2298783-A1 | Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections | Yale University (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20100048500-A1 | Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048500-A1 | Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections | TYMP, ITPA, SAMHD1 | TOP2A 144/4885TK1 91/4885DHFR 262/4885 |
| US-20120252751-A1 | ANTI-VIRAL NUCLEOSIDE ANALOGS AND METHODS FOR TREATING VIRAL INFECTIONS, ESPECIALLY HIV INFECTIONS | TYMP, ITPA, SAMHD1 | TOP2A 144/4885TK1 91/4885DHFR 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.